PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.

Author: Abou SalehLina, AragonIleana V, BoydAbigail, KolotevaAnna, McDonoughWill, MurphyJames M, RichJustin, RichterWito

Paper Details 
Original Abstract of the Article :
Inhibitors of cAMP-phosphodiesterase 4 (PDE4) exert a number of promising therapeutic benefits, but adverse effects, in particular emesis and nausea, have curbed their clinical utility. Here, we show that PAN-selective inhibition of PDE4, but not inhibition of PDE3, causes a time- and dose-dependent...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/32738081

データ提供:米国国立医学図書館(NLM)

PDE4 Inhibition: A Double-Edged Sword for Gastroparesis

Inhibitors of cAMP-phosphodiesterase 4 (PDE4) hold promise for treating various conditions, but adverse effects, including nausea and emesis, have hindered their clinical utility. This study investigates the impact of PAN-selective PDE4 inhibition on gastric emptying in mice. The researchers observed a time- and dose-dependent accumulation of food in the stomachs of mice, suggesting that PDE4 inhibition might impair gastric emptying, potentially contributing to nausea and emesis.

PDE4 Inhibition: A Potential Culprit for Gastroparesis

This study reveals a potential link between PDE4 inhibition and gastroparesis, a condition characterized by delayed gastric emptying and associated with nausea and vomiting. The researchers' findings highlight the importance of considering the potential gastrointestinal side effects of PDE4 inhibitors and carefully balancing therapeutic benefits with potential risks. Further research is needed to explore the mechanisms underlying PDE4 inhibition-induced gastroparesis and develop strategies to mitigate these adverse effects.

Gastroparesis: Understanding the Mechanisms and Mitigation

This study underscores the need for a thorough understanding of the mechanisms underlying gastroparesis and the potential role of PDE4 inhibition in its development. The researchers' findings emphasize the importance of careful patient selection and monitoring for potential side effects when using PDE4 inhibitors. Further research into alternative therapeutic strategies, including potential prokinetic agents, might be beneficial in mitigating the gastrointestinal side effects associated with PDE4 inhibition.

Dr.Camel's Conclusion

Just like a camel navigating a treacherous desert path, understanding the complex interplay between PDE4 inhibition and gastroparesis requires careful consideration. This study highlights the potential for PDE4 inhibition to contribute to gastroparesis, underscoring the need for careful patient selection, monitoring for side effects, and exploring alternative treatment strategies to optimize therapeutic benefits while minimizing adverse effects.

Date :
  1. Date Completed 2021-03-11
  2. Date Revised 2021-09-03
Further Info :

Pubmed ID

32738081

DOI: Digital Object Identifier

NIHMS1674101

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.